|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Llovet JM: Prognostic
prediction and treatment strategy in hepatocellular carcinoma.
Hepatology. 35:519–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Belghiti J and Fuks D: Liver resection and
transplantation in hepatocellular carcinoma. Liver Cancer. 1:71–82.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee Cheah Y and P KHC: Liver
transplantation for hepatocellular carcinoma: An appraisal of
current controversies. Liver Cancer. 1:183–189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin SM: Local ablation for hepatocellular
carcinoma in Taiwan. Liver Cancer. 2:73–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada S, Kawaguchi A, Kawaguchi T,
Fukushima N, Kuromatsu R, Sumie S, Takata A, Nakano M, Satani M,
Tonan T, et al: Serum albumin level is a notable profiling factor
for non-B, non-C hepatitis virus-related hepatocellular carcinoma:
A data-mining analysis. Hepatol Res. 44:837–845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tateishi R, Uchino K, Fujiwara N, Takehara
T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura
T, et al: A nationwide survey on non-B, non-C hepatocellular
carcinoma in Japan: 2011–2015 update. J Gastroenterol. 54:367–376.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marasco G, Colecchia A, Colli A, Ravaioli
F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M and Festi
D: Role of liver and spleen stiffness in predicting the recurrence
of hepatocellular carcinoma after resection. J Hepatol. 70:440–448.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishikawa H, Kita R, Kimura T and Osaki Y:
Transcatheter arterial embolic therapies for hepatocellular
carcinoma: A literature review. Anticancer Res. 34:6877–6886.
2014.PubMed/NCBI
|
|
10
|
Bruix J, Sala M and Llovet JM:
Chemoembolization for hepatocellular carcinoma. Gastroenterology.
127 (5 Suppl 1):S179–S188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takayasu K, Arii S, Ikai I, Omata M, Okita
K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, et al:
Prospective cohort study of transarterial chemoembolization for
unresectable hepatocellular carcinoma in 8510 patients.
Gastroenterology. 131:461–469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ando E, Tanaka M, Yamashita F, Kuromatsu
R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K and Sata M:
Hepatic arterial infusion chemotherapy for advanced hepatocellular
carcinoma with portal vein tumor thrombosis: Analysis of 48 cases.
Cancer. 95:588–595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takeda H, Nishikawa H, Osaki Y, Tsuchiya
K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y and Izumi N;
Japanese Red Cross Liver Study Group, : Clinical features
associated with radiological response to sorafenib in unresectable
hepatocellular carcinoma: A large multicenter study in Japan. Liver
Int. 35:1581–1589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu
H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N,
Matsukuma N, et al: Efficacy, safety, and survival factors for
sorafenib treatment in Japanese patients with advanced
hepatocellular carcinoma. Oncology. 84:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uraki J, Yamakado K, Nakatsuka A and
Takeda K: Transcatheter hepatic arterial chemoembolization for
hepatocellular carcinoma invading the portal veins: Therapeutic
effects and prognostic factors. Eur J Radiol. 51:12–18. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piscaglia F and Ogasawara S: Patient
selection for transarterial chemoembolization in hepatocellular
carcinoma: Importance of benefit/risk assessment. Liver Cancer.
7:104–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiraoka A, Kumada T, Kudo M, Hirooka M,
Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, et al:
Hepatic function during repeated TACE procedures and prognosis
after introducing sorafenib in patients with unresectable
hepatocellular carcinoma: Multicenter analysis. Dig Dis.
35:602–610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang W, Zhao Y, Bai W and Han G: Response
assessment for HCC patients treated with repeated TACE: The optimal
time-point is still an open issue. J Hepatol. 63:1530–1531. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikeda M, Mitsunaga S, Shimizu S, Ohno I,
Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, et
al: Efficacy of sorafenib in patients with hepatocellular carcinoma
refractory to transcatheter arterial chemoembolization. J
Gastroenterol. 49:932–940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ogasawara S, Chiba T, Ooka Y, Kanogawa N,
Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M and Yokosuka
O: Efficacy of sorafenib in intermediate-stage hepatocellular
carcinoma patients refractory to transarterial chemoembolization.
Oncology. 87:330–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Jesus VHF and Dettino ALA: Update on
hepatocellular carcinoma from the 2018 gastrointestinal cancer
symposium (ASCO GI). J Hepatocell Carcinoma. 5:87–90. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kudo M: Proposal of primary endpoints for
TACE combination trials with systemic therapy: Lessons learned from
5 negative trials and the positive TACTICS trial. Liver Cancer.
7:225–234. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heimbach JK, Kulik LM, Finn RS, Sirlin CB,
Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: AASLD
guidelines for the treatment of hepatocellular carcinoma.
Hepatology. 67:358–380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cholongitas E, Papatheodoridis GV, Vangeli
M, Terreni N, Patch D and Burroughs AK: Systematic review: The
model for end-stage liver disease-should it replace Child-Pugh's
classification for assessing prognosis in cirrhosis? Aliment
Pharmacol Ther. 22:1079–1089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Healey JE Jr, Schroy PC and Sorensen RJ:
The intrahepatic distribution of the hepatic artery in man. J Int
Coll Surg. 20:133–148. 1953.PubMed/NCBI
|
|
30
|
Horikawa M, Miyayama S, Irie T, Kaji T and
Arai Y: Development of conventional transarterial chemoembolization
for hepatocellular carcinomas in Japan: Historical, strategic, and
technical review. AJR Am J Roentgenol. 205:764–773. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lammer J, Malagari K, Vogl T, Pilleul F,
Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S,
et al: Prospective randomized study of doxorubicin-eluting-bead
embolization in the treatment of hepatocellular carcinoma: Results
of the PRECISION V study. Cardiovasc Intervent Radiol. 33:41–52.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
D'Amico F, Schwartz M, Vitale A, Tabrizian
P, Roayaie S, Thung S, Guido M, del Rio Martin J, Schiano T and
Cillo U: Predicting recurrence after liver transplantation in
patients with hepatocellular carcinoma exceeding the up-to-seven
criteria. Liver Transpl. 15:1278–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kokudo N, Hasegawa K, Akahane M, Igaki H,
Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al:
Evidence-based clinical practice guidelines for hepatocellular
carcinoma: The Japan society of hepatology 2013 update (3rd JSH-HCC
Guidelines). Hepatol Res. 45:2015. View Article : Google Scholar
|
|
35
|
Han K and Kim JH: Transarterial
chemoembolization in hepatocellular carcinoma treatment: Barcelona
clinic liver cancer staging system. World J Gastroenterol.
21:10327–10335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bolondi L, Burroughs A, Dufour JF, Galle
PR, Mazzaferro V, Piscaglia F, Raoul JL and Sangro B: Heterogeneity
of patients with intermediate (BCLC B) hepatocellular carcinoma:
Proposal for a subclassification to facilitate treatment decisions.
Semin Liver Dis. 32:348–359. 2012.PubMed/NCBI
|
|
37
|
Yamakado K and Hirota S:
Sub-classification of intermediate-stage (Barcelona Clinic Liver
Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol.
21:10604–10608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arizumi T, Ueshima K, Minami T, Kono M,
Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, et al:
Effectiveness of sorafenib in patients with transcatheter arterial
chemoembolization (TACE) refractory and intermediate-stage
hepatocellular carcinoma. Liver Cancer. 4:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai
H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, et al:
Prospective study of transcatheter arterial chemoembolization for
unresectable hepatocellular carcinoma: An Asian cooperative study
between Japan and Korea. J Vasc Interv Radiol. 24:490–500. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sergio A, Cristofori C, Cardin R, Pivetta
G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A and
Farinati F: Transcatheter arterial chemoembolization (TACE) in
hepatocellular carcinoma (HCC): The role of angiogenesis and
invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rezaĭkina AV and Komarova VD: An
immunoenzyme method of detecting anti-DNA antibodies in lupus
erythematosus. Lab Delo. 40–43. 1988.(In Russian).
|
|
42
|
Chen B, Liu J, Wang X, Shen Q, Li C and
Dai C: Co-expression of PDGF-B and VEGFR-3 strongly correlates with
poor prognosis in hepatocellular carcinoma patients after
hepatectomy. Clin Res Hepatol Gastroenterol. 42:126–133. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen L, Shi Y, Jiang CY, Wei LX, Wang YL
and Dai GH: Expression and prognostic role of pan-Ras, Raf-1, pMEK1
and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg
Oncol. 37:513–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yan W, Zhu Z, Pan F, Huang A and Dai GH:
Overexpression of c-kit(CD117), relevant with microvessel density,
is an independent survival prognostic factor for patients with
HBV-related hepatocellular carcinoma. Onco Targets Ther.
11:1285–1292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Weintraub JL and Salem R: Treatment of
hepatocellular carcinoma combining sorafenib and transarterial
locoregional therapy: State of the science. J Vasc Interv Radiol.
24:1123–1134. 2013. View Article : Google Scholar : PubMed/NCBI
|
